Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
ELCC 2018
The 8th European Lung Cancer Conference
Access to all presentations that took place at ELCC 2018 in Geneva, Switzerland
Presentation Date(s):- Apr 11 - 14, 2018
- Total Presentations: 407
-
+
Immunotherapy and next-generation TKIs: From second to frontline treatment
- Type: Poster Discussion session
- Presentations: 18
- Moderators:P. Garrido Lopez
- Coordinates: 4/12/2018, 07:45 - 09:00, Room A
-
+
140PD - Complex epidermal growth factor receptor (EGFR) mutations and responses to tyrosine kinase inhibitors (TKIs) in advanced lung adenocarcinomas
10:54 - 10:54 | Presenter: B. Zhang
- Abstract
Loading...
-
+
Poster Display session (Friday)
- Type: Poster Display session
- Presentations: 197
- Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
-
+
61P - mir-125b plays a tumor suppressor role in inflammation-related non-small cell lung cancer via repressing IGF-1 signal pathway
12:30 - 12:30 | Presenter: Y. Zhang
- Abstract
Loading... -
+
92P - Expression of TNFRII in serum is correlated with the significant risk of subcentimeter lung adenocarcinoma
12:30 - 12:30 | Presenter: Y. Zhang
- Abstract
Loading... -
+
100P - Prognostic factors in surgically resected N2 small cell lung cancer: Significance of the subcarinal node
12:50 - 12:50 | Presenter: R. Qiao
- Abstract
Loading... -
+
167P - Efficacy of pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with ROS-1 rearrangement
12:50 - 12:50 | Presenter: B. Zhang
- Abstract
Loading... -
+
174P - Aprepitant, palonosetron and dexamethasone proved effective to prevent chemotherapy-related nausea and vomiting in lung cancer
12:50 - 12:50 | Presenter: Y. Zhang
- Abstract
Loading...
-
+
ESMO-IASLC Best Abstracts
- Type: Best Abstract session
- Presentations: 7
- Moderators:M. Perol
- Coordinates: 4/13/2018, 16:45 - 18:30, Room B
-
+
91O - Adjuvant chemotherapy candidates in stage I lung adenocarcinomas following complete lobectomy: What does an analysis based on recurrence risk stratification tell us?
16:45 - 17:00 | Presenter: J. Qian
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
233O - Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: Post-hoc analysis of PACIFIC patient-reported outcomes
17:15 - 17:30 | Author(s): R. Hui
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
